SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX) Files An 8-K Submission of Matters to a Vote of Security Holders

SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.

Story continues below

Submission of Matters to a Vote of Security Holders.

Syndax Pharmaceuticals, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on May 23, 2018. The results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting are set forth below. The proposals set forth below are described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 10, 2018.The voting results were as follows:

Proposal 1:The Company’s stockholders elected both nominees for director to serve a three-year term until the 2021 Annual Meeting, or until their respective successors are duly elected and qualified, by the votes set forth in the table below:

Nominee

For

Against

Broker Non-Votes

Henry Chen

10,313,293

1,800,907

5,278,332

Luke Evnin, Ph.D.

10,077,732

2,036,778

5,278,332

Proposal 2:The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018 by the votes set forth in the table below:

For

Against

Abstain

17,360,374

21,049

13,946


About SYNDAX PHARMACEUTICALS, INC. (NASDAQ:SNDX)

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer. It is developing entinostat, which has direct effects on both cancer cells and immune regulatory cells, and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy. Entinostat is being evaluated as a combination therapeutic in Phase Ib/II clinical trials with Merck & Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer.

An ad to help with our costs